You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Rituximab(HLX01)

Showing 1 - 25 of 2,068
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

Recruiting
  • Lymphoma, B-Cell
  • Rituximab Biosimilar
  • Pegylated Interferon α-2b
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022

B-cell Non Hodgkin's Lymphoma Trial (HLX01, Rituximab)

Completed
  • B-cell Non Hodgkin's Lymphoma
  • (no location specified)
May 4, 2022

B-cell Non Hodgkin's Lymphoma Trial in Beijing (HLX01, Rituximab, CHOP)

Completed
  • B-cell Non Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 4, 2022

Rheumatoid Arthritis Trial (HLX01)

Completed
  • Rheumatoid Arthritis
  • (no location specified)
May 4, 2022

IgA Nephropathy Trial in Shanghai (Rituximab, RAS 2410)

Recruiting
  • IgA Nephropathy
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Sep 28, 2021

CD20-positive Follicular Lymphoma, With Low Tumour Burden Trial (HLX01, Mabthera®)

Withdrawn
  • CD20-positive Follicular Lymphoma, With Low Tumour Burden
  • (no location specified)
Dec 10, 2020

Diffuse Large B Cell Lymphoma Trial in Beijing

Enrolling by invitation
  • Diffuse Large B Cell Lymphoma
    • Beijing, China
      Cancer Institute/Hospital, Chinese Academy of Medical Sciences &
    Jul 25, 2020

    Moderately to Severely Active Rheumatoid Arthritis Trial in Jiujiang (HLX01, Methotrexate(MTX))

    Completed
    • Moderately to Severely Active Rheumatoid Arthritis
    • Jiujiang, Jiangxi, China
      Jiujiang No.1 peoples's hospital
    May 4, 2022

    Frequently Relapsing Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome Trial in Shanghai (Rituximab, Mycophenolate

    Withdrawn
    • Frequently Relapsing Nephrotic Syndrome
    • Steroid-Dependent Nephrotic Syndrome
    • Shanghai, Shanghai, China
    • +3 more
    Dec 25, 2020

    Limited Stage Small Cell Lung Cancer Trial (HLX10, hypofractionated radiotherapy, Prophylactic Cranial Irradiation (PCI))

    Not yet recruiting
    • Limited Stage Small Cell Lung Cancer
    • (no location specified)
    Jun 29, 2022

    Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)

    Active, not recruiting
    • Malignant Solid Neoplasm
    • Biopsy
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Nov 15, 2023

    Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,

    Recruiting
    • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
    • +13 more
    • Scottsdale, Arizona
    • +2 more
    Jun 1, 2022

    Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

    Recruiting
    • Recurrent Acute Lymphoblastic Leukemia
    • +10 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 21, 2022

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With

    Recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +5 more
    • Blinatumomab
    • +8 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 1, 2022

    COVID19 Vaccination, Rituximab, Immunosuppression Trial in Bern (History of exposure to anti-CD20 treatment since 01/01/2010,

    Recruiting
    • COVID19 Vaccination
    • +2 more
    • History of exposure to anti-CD20 treatment since 01/01/2010
    • Completion of COVID19 vaccine at least 4 weeks ago
    • Bern, BE, Switzerland
      University Hospital Bern Inselspital
    May 27, 2021

    Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in

    Terminated
    Has Results
    • Philadelphia Chromosome Negative
    • +2 more
    • Blinatumomab
    • +11 more
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 3, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Los Angeles, California
    • +4 more
    Jul 19, 2022

    Ophthalmopathy, Thyroid-Associated Trial in Gothenburg, Mölndal, Stockholm (Rituximab, Iv Methylprednisolone, peroral

    Active, not recruiting
    • Ophthalmopathy, Thyroid-Associated
    • Gothenburg, Sweden
    • +4 more
    Sep 17, 2021

    Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Worldwide (drug, biological, radiation)

    Recruiting
    • Primary Mediastinal (Thymic) Large B-Cell Lymphoma
    • Birmingham, Alabama
    • +187 more
    Jan 31, 2023

    Lymphoma, Large B-Cell, Diffuse, CNS Tumors, Primary Trial in France (Lenalidomide, Ibrutinib)

    Recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • Central Nervous System Neoplasms, Primary
    • Amiens, France
    • +26 more
    Nov 30, 2022

    Safety and Efficacy of Biosimilar Rituximab

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
      • Campinas, São Paulo, Brazil
        Dr Fernando Pericole
      Jun 9, 2021

      Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

      Recruiting
      • Marginal Zone Lymphoma
      • +2 more
      • Yvoir, Belgium
      • +36 more
      Nov 4, 2022

      Metastatic Cancer, Solid Tumor, Advanced Cancer Trial in Korea, Republic of, United States (Evorpacept (ALX148), Pembrolizumab,

      Active, not recruiting
      • Metastatic Cancer
      • +3 more
      • Evorpacept (ALX148)
      • +5 more
      • Denver, Colorado
      • +9 more
      Jul 20, 2022

      Tumors Trial in Worldwide (CC-95251, Rituximab, Cetuximab)

      Recruiting
      • Neoplasms
      • Birmingham, Alabama
      • +62 more
      Jan 19, 2023

      CD20+ Follicular Lymphoma Trial in Worldwide (Duvelisib, Rituximab, Obinutuzumab)

      Terminated
      Has Results
      • CD20+ Follicular Lymphoma
      • Los Angeles, California
      • +20 more
      Mar 15, 2021